אנזלוטמיד טבע 40 מ"ג
ENZALUTAMIDE TEVA 40 MG

ENZALUTAMIDE TEVA 40 MG is Indicated for:

• As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

• In combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC).

• For the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC).

• For the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

• For the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.